ESC 2023 Valvular Heart Disease Guidelines: Key Decisions & Intervention Timing

Abstract

The 2023 European Society of Cardiology (ESC) Guidelines for the management of Valvular Heart Disease (VHD) present significant updates that refine the timing and mode of intervention, particularly for Aortic Stenosis (AS) and Mitral Regurgitation (MR). 

The guidelines strongly endorse the Heart Team approach as central to decision-making across all complex VHD presentations. Key advancements include reinforcing Transcatheter Aortic Valve Implantation (TAVI) as the preferred strategy for severe AS in most patients aged 75 and older and those at high surgical risk, while preserving Surgical Aortic Valve Replacement (SAVR) for younger, low-risk patients. 

Furthermore, the criteria for Transcatheter Edge-to-Edge Repair (TEER) in secondary MR are clarified, emphasizing its role in patients refractory to Guideline-Directed Medical Therapy (GDMT) and meeting specific clinical and echocardiographic criteria, based primarily on positive outcomes from major randomized trials. 

These updates aim to leverage evolving interventional technologies to improve patient outcomes while maintaining a strong evidence base for intervention timing in both symptomatic and high-risk asymptomatic VHD.

Introduction

Valvular heart disease (VHD) represents a significant global health burden, contributing substantially to morbidity, mortality, and healthcare costs, particularly in aging populations.

With the prevalence of degenerative etiologies, such as aortic stenosis (AS) and mitral regurgitation (MR), projected to rise, timely and accurate management decisions are paramount for preserving ventricular function and improving long-term outcomes. 

The introduction of transcatheter therapies, including Transcatheter Aortic Valve Implantation (TAVI) and Transcatheter Edge-to-Edge Repair (TEER), has revolutionized the treatment landscape, moving VHD management beyond purely surgical paradigms. 

The 2023 European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease serve as a critical reference point, synthesizing recent randomized controlled trial data to refine the complex decision-making process, especially regarding the optimal timing of intervention for asymptomatic patients and the selection between surgical and transcatheter approaches based on individual patient risk and anatomical suitability. 

This article summarizes the core updates, focusing on the refined decision algorithms for severe AS and MR.

Aortic Stenosis: Refining the TAVR vs. SAVR Decision

Diagnosis and Risk Stratification

The diagnosis of Severe AS relies on established echocardiographic criteria: an aortic valve velocity (Vmax) ≥ 4.0 m/s, a mean pressure gradient (ΔPmean) ≥ 40 mmHg, and an aortic valve area (AVA) ≤ 1.0 cm² (or ≤ 0.6 cm²/m² indexed).

The guidelines recognize the importance of identifying specific phenotypes, particularly low-flow, low-gradient AS, which requires careful differentiation using dobutamine stress echocardiography to distinguish true severe AS from pseudo-severe AS. Risk stratification for intervention remains centered on:

• Surgical Risk: Evaluated using established scoring systems (e.g., STS, EuroSCORE II) and refined by clinical frailty assessment.
  
  
• Anatomic Feasibility: Assessment of valve morphology, annular size, and vascular access suitability for TAVI.
  
  

Timing of Intervention: Symptomatic and Asymptomatic AS

Intervention is a Class I recommendation for all patients with symptomatic severe AS. Symptoms, including syncope, angina, or heart failure, signal a critical stage warranting prompt treatment.

A key focus of the 2023 update is the expanded role for early intervention in asymptomatic severe AS. Intervention (TAVI or SAVR) is a Class IIa recommendation for asymptomatic patients with severe AS who present with markers of high risk, including:

• Significant LV dysfunction (LVEF < 50%) without another cause.
  
  
• Development of pulmonary hypertension (sPAP > 60 mmHg at rest).
  
  
• Decreased exercise tolerance or symptomatic hypotension during exercise testing.
  
  
• Very severe AS (Vmax > 5.0 m/s or ΔPmean > 60 mmHg) and low surgical risk.
  
  

Choice of Intervention: TAVR vs. SAVR

The choice between TAVI and SAVR is now primarily driven by patient age, surgical risk, and anatomical considerations, reflecting the robust long-term data from trials like PARTNER and CoreValve.

The guidelines emphasize the concept of Lifetime Management, where the initial choice (TAVI or SAVR) must consider the patient’s expected longevity and the potential need for future valve-in-valve procedures. 

SAVR remains the treatment of choice when concomitant cardiac surgery is required (e.g., coronary artery bypass grafting, other valve repair).

Mitral Regurgitation: Transcatheter Edge-to-Edge Repair (TEER)

Distinguishing Primary (Organic) vs. Secondary (Functional) MR

The fundamental difference in management stems from etiology:

• Primary MR (PMR): Caused by structural pathology of the valve apparatus (e.g., prolapse, flail leaflet, chordal rupture). Intervention directly targets the leaflet defect.
  
  
• Secondary MR (SMR): Caused by adverse remodeling of the left ventricle (LV), leading to leaflet tethering and incomplete coaptation (common in heart failure and dilated cardiomyopathy). Management prioritizes Guideline-Directed Medical Therapy (GDMT) for the underlying heart failure.
  
  

Intervention Timing for Primary MR

Surgical mitral valve repair or replacement (MVR) remains the Class I recommendation for symptomatic patients with severe PMR and those with severe asymptomatic PMR presenting with LV dysfunction (LVEF ≤ 60%, or LVESD ≥ 40 mm).

The role of TEER in primary MR is reserved for patients:

• Deemed at high or prohibitive surgical risk by the Heart Team.
  
  
• Presenting with suitable anatomy for the procedure.
  
  

Intervention for Secondary MR: Role of TEER**

The guidelines strongly reiterate that management of SMR is first and foremost optimal GDMT for heart failure and volume status optimization. Once GDMT is optimized and MR remains severe, the decision to pursue intervention is based on the robust data from trials such as COAPT.

TEER is a Class IIa recommendation for symptomatic patients with severe SMR despite optimal GDMT (including cardiac resynchronization therapy if indicated), provided they meet specific clinical and echocardiographic criteria:

• The patient is symptomatic (NYHA Class II–IV).
  
  
• LV size is not excessively dilated (LVEDD ≤ 70 mm), and the LVEF is between 20% and 50%.
  
  

The criteria for TEER application in SMR are designed to identify the cohort most likely to benefit, aligning with the positive outcomes seen in COAPT, which demonstrated reduced heart failure hospitalizations and improved survival in selected patients. 

Patients with unfavourable anatomical characteristics or disproportionately severe LV dysfunction (LVEF < 20%) are considered to have a less favourable risk-benefit profile for the procedure.

Comorbidities and Special Considerations

The 2023 ESC guidelines place significant emphasis on incorporating comorbidities and specific patient populations into the valvular heart disease (VHD) decision-making process, moving beyond isolated valve pathology. 

These factors frequently influence the risk assessment, the choice between surgical versus transcatheter approaches, and long-term prognosis.

Chronic Kidney Disease (CKD):

• Impact on Risk: CKD, especially advanced stages, significantly elevates the surgical risk associated with SAVR due to bleeding risk and the potential for requiring dialysis.
  
  
• TAVI Preference: For severe Aortic Stenosis (AS) patients with severe CKD or on dialysis, TAVI is often the preferred strategy, regardless of age, provided the anatomy is suitable, as it offers a less invasive approach.
  However, the durability of bioprosthetic valves in the context of hyperphosphatemia and accelerated calcification must be considered during Heart Team discussions.
  
  
• Iodinated Contrast: Careful attention must be paid to minimizing the use of iodinated contrast during transcatheter procedures to prevent acute kidney injury (AKI).
  
  

Atrial Fibrillation (AF) and Anticoagulation:

• The presence of AF is a common comorbidity that compounds the risk of stroke in VHD patients, particularly those with Mitral Stenosis or Mechanical Valves.
  
  
• Post-TAVI Antithrombotic Strategy: Following TAVI, the guidelines recommend a concise period of dual antiplatelet therapy or single antiplatelet therapy plus oral anticoagulation (OAC) for patients requiring long-term OAC (e.g., due to AF). The duration and combination depend on the individual bleeding and thromboembolic risk, though single antiplatelet therapy is generally favoured for those without an OAC indication.
  
  
• Timing of Intervention: New-onset AF is recognized as a potential marker of myocardial deterioration in asymptomatic severe Primary Mitral Regurgitation (PMR), supporting a Class IIa recommendation for earlier surgical intervention in this subgroup, even without meeting standard LVEF or LVESD thresholds.
  
  

Heart Failure (HF) Phenotype:

• The management of severe Secondary Mitral Regurgitation (SMR) is inextricably linked to the management of underlying HF. Successful TEER candidates are those whose HF remains symptomatic despite maximal Guideline-Directed Medical Therapy (GDMT).
  
  
• Patients presenting with severe valve disease and advanced HF often represent a challenging population where the Heart Team must carefully weigh the immediate procedural risk against the potential for reversing ventricular remodeling and improving quality of life. The presence of significant pulmonary hypertension or right ventricular dysfunction increases the risk for any intervention.
  
  

Clinical Practice Summary & Key Takeaways

The 2023 ESC Valvular Heart Disease guidelines underscore a fundamental shift toward earlier, personalized, and technology-driven interventions. The core message is the necessity of adopting a multidisciplinary, data-driven approach, summarized below.

Practice Highlights: Key Class I Recommendations

Integrating Transcatheter Therapies

1. Aortic Stenosis (AS): The decision between TAVI and SAVR is cemented as primarily age-dependent. TAVI is established as the preferred treatment for patients aged ≥ 75 years and for all patients at high surgical risk, reflecting strong long-term safety data. SAVR retains its primacy for younger patients (typically < 65–70 years) where long-term valve durability is the paramount consideration.
   
   
2. Mitral Regurgitation (MR): The role of TEER for Secondary MR (SMR) is refined. It is confirmed as a valuable addition for carefully selected, symptomatic patients whose heart failure is refractory to Guideline-Directed Medical Therapy (GDMT), provided they meet specific criteria (e.g., LVEF 20-50%, non-excessively dilated LV). This selection process emphasizes the importance of clinical trial criteria (COAPT) in real-world practice.
   
   

Guiding Principles for Decision-Making

• Heart Team Approach: The specialized VHD Heart Team, comprising cardiologists (interventional and non-interventional), cardiac surgeons, and imaging specialists, is mandated for all complex, high-risk, or asymptomatic patients being considered for intervention.
  
  
• Optimal Timing: The guidelines encourage intervening on certain high-risk, asymptomatic patients with severe AS (e.g., very severe velocity, exercise intolerance) and PMR (e.g., new-onset AF) before the development of irreversible myocardial damage, moving the therapeutic window earlier in the disease course.
  
  
• Comorbidity Management: Coexisting conditions, particularly CKD and Atrial Fibrillation, significantly modulate procedural risk and long-term anticoagulation strategy, necessitating individualized risk-benefit assessments.
  
  

The ESC 2023 guidelines provide the necessary framework to translate high-quality evidence into precise, patient-centered management strategies, ensuring optimal application of surgical and transcatheter technologies.